Skip to main content
SpringerLink
Log in

Complement in diseases of the nervous system

  • Chapter
Complement in Health and Disease

Part of the book series: Immunology and Medicine ((IMME,volume 20))

Abstract

Tissue damage in many neurological diseases is mediated, at least in part, by components of the immune system. Both cellular and humoral elements have been implicated and immune complex deposition demonstrated. This chapter fo-cusses on the evidence implicating complement in these diseases. Excellent reviews of the role of the immune system in the pathogenesis of several neurological diseases exist, and the interested reader is urged to consult these to obtain a less focussed overview.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Matthews, B. (1987). Multiple sclerosis. Med. Int., 47, 1961–1966

    Google Scholar 

  2. Rodriguez, M. (1989). Multiple sclerosis: Basic concepts and hypothesis. Mayo Clin. Proc, 64, 570–576

    PubMed  CAS  Google Scholar 

  3. Sayetta, R. B. (1986). Theories of the etiology of multiple sclerosis. J. Clin. Lab. Immunol., 21, 55–70

    PubMed  CAS  Google Scholar 

  4. Tourtellotte, W. V. (1989). Current concepts about multiple sclerosis. Mayo Clin. Proc, 64, 592–597

    PubMed  CAS  Google Scholar 

  5. Lowenthal A. Van Sande M. and Karcher D. 1960. The differential diagsis of neurological diseases by fractionating electrophoretically the CSF gamma globulins. J. Neurochem. 6 51–5

    Google Scholar 

  6. Tourtellotte W. W. and Parker J. A. 1966. Multiple sclerosis Correlation between immuglobulin G in cerebrospinal fluid and brain. Science 154 1044–104

    Google Scholar 

  7. Dasgupta, M. K., Warren, K. G., Johny, K. V. and Dassetor, J. B. (1982). Circulating immune complexes in multiple sclerosis: relation with disease activity. Neurology, 32, 1000–1004

    Article  PubMed  CAS  Google Scholar 

  8. Salmi, A., Ziola, B., Reunaanen, M., Julkinen, I. and Wager, O. (1982). Immune complexes in serum and cerebrospinal fluid of multiple sclerosis patients and patients with other neurological disorders. Acta Neurol. Scand., 66, 1–15

    Article  PubMed  CAS  Google Scholar 

  9. Prineas, J. W. and Wright, R. G. (1978). Macrophages, lymphocytes and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest., 38, 409–421

    PubMed  CAS  Google Scholar 

  10. Traugott, U. (1985). Characterization and distribution of lymphocyte subpopulations in multiple sclerosis plaques versus autoimmune demyelinating lesions. Springer Semin. ImmunopathoL, 8, 71–95

    Article  PubMed  CAS  Google Scholar 

  11. Kabat, E. A., Glusman, M. and Knaub, V. (1948). Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am. J. Med., 4, 653–662

    Article  PubMed  CAS  Google Scholar 

  12. Vandvick, B. (1977). Oligoclonal IgG and free light chains in the cerebrospinal fluid of patients with multiple sclerosis and infectious diseases of the central nervous system. Scand. J. Immunol., 6, 913–922

    Article  Google Scholar 

  13. Ryberg, B. (1982). Antibrain antibodies in multiple sclerosis: relation to clinical variables. J.Neurol. Sci., 54, 239–261

    Article  PubMed  CAS  Google Scholar 

  14. Cerf, G. A. and Carels, G. (1966). Multiple sclerosis: serum factor producing reversible alteration in bioelectric responses. Science, 152, 1066–1068

    Article  PubMed  CAS  Google Scholar 

  15. Schauf, C. L. and Davis, F. A. (1978). The occurrence, specificity and role of neuroelectric blocking factors in multiple sclerosis. Neurology, 28, 34–39

    Article  PubMed  CAS  Google Scholar 

  16. Bornstein, M. D. and Crain, S. M. (1965). Functional studies of cultured brain tissues as related to demyelinative disorders. Science, 148, 1242–1244

    Article  PubMed  CAS  Google Scholar 

  17. Raine, C. S., Hummelglard, A., Swanson, E. and Bornstein, M. B. (1973). Multiple sclerosis serum induced demyelination in vitro. A light and electron microscopic study. J. Neurol. Sci., 20, 127–139

    Article  PubMed  CAS  Google Scholar 

  18. Tabira, T., Wolfgran, F. J., Webster, H., Wray, S. H. and McFarlin, D. E. (1977). Myelotoxicity of CSF fractions from multiple sclerosis patients tested in an in vivo model. Neurology, 27, 374–383

    Article  Google Scholar 

  19. Grundke-Iqbal I. and Bornstein M. B. 1980. Multiple sclerosis-serum gamma globulins and demyelination in organ culture. Neurology; 30 749–75

    Google Scholar 

  20. Liu, W. T., Vanguri, P. and Shin, M. L. (1983). Studies on demyelination in vitro: the requirements of membrane attack components of the complement system. J. Immunol., 131, 778–782

    PubMed  CAS  Google Scholar 

  21. Silverman B. A. Carney D. F. Johnston C. A. Vanguri P. and Shin M. L. 1984. Isolation of membrane attack complex of complement from myelin membranes treated with serum complement. J. Neurochem. 42 1024–102

    Google Scholar 

  22. Schlaepfer, W. W. (1977). Vesicular disruption of myelin stimulated by exposure of nerve to calcium ionophore. Nature, 265, 734–736

    Article  PubMed  CAS  Google Scholar 

  23. Morgan, B. P. and Campbell, A. K. (1985). The recovery of human polymorphonuclear leucoytes from sublytic complement attack is mediated by changes in intracellular free calcium. Biochem. J., 231, 205–208

    PubMed  CAS  Google Scholar 

  24. Vanguri, P. and Shin, M. L. (1988). Hydrolysis of myelin basic protein in human myelin by terminal complement complexes. J. Biol. Chem., 263, 7228–7234

    PubMed  CAS  Google Scholar 

  25. Cyong, J. C, Witkin, S. S., Reiger, B., Barbarese, E., Good, R. A. and Day, N. K. (1982). Antibody-independent complement activation by myelin via the classical complement pathway. J. Exp. Med., 155, 587–598

    Article  PubMed  CAS  Google Scholar 

  26. Vanguri, P., Koski, C. L., Silverman, B. and Shin, M. L. (1982). Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies. Proc. Natl. Acad. Sci. USA, 79, 3920–3934

    Article  Google Scholar 

  27. Tanaka, M. and Cyong, J. C. (1985). The development of complement-activating ability as an age-related factor in murine brains. Microbiol. Immunol., 29, 1219–1227

    PubMed  CAS  Google Scholar 

  28. Scolding, N. J., Morgan, B. P., Houston, W. A. J., Campbell, A. K., Linington, C. and Compston, D. A. S. (1989). Normal rat serum cytotoxicity against syngenic oligodendrocytes: complement activation and attack in the absence of antimyelin antibodies. J. Neurol. Sci., 89, 289–300

    Article  PubMed  CAS  Google Scholar 

  29. Scolding, N. J., Morgan, B. P., Houston, W. A. J., Linington, C, Campbell, A. K. and Compston, D. A. S. (1989) Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature (London), 339, 620–622

    Article  CAS  Google Scholar 

  30. Wren, D. R. and Noble, M. (1989). Oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody. Proc. Natl. Acad. Sci. USA, 86, 9025–9029

    Article  PubMed  CAS  Google Scholar 

  31. Scolding N. J. Morgan B. P. Campbell A. K. and Compston D. A. S. 1990. Complement-mediated serum cytotoxicity against oligodendrocytes a comparison with other cells of the oligodendrocyte-type II astrocyte lineage. J. Neurol. Sci. 97 155–16

    Google Scholar 

  32. Shirazi Y. Imagawa D. K. and Shin M. L. 1987. Release of leukotriene B4 from sublethally injured oligodendrocytes by terminal complement complexes. J. Neurochem., 48, 171–17

    Article  Google Scholar 

  33. Shirazi Y. McMorris F. A. and Shin M. L. 1989. Arachidonic acid mobilization and phosphoisitide turver by the terminal complement complex C5b-9 in rat oligodendrocyte X C6 glioma cell hybrids. J. Immul. 142 4285–429

    Google Scholar 

  34. Scolding, N. J., Houston, W. A. J., Morgan, B. P., Campbell, A. K. and Compston, D. A. S. (1989). Reversible injury of cultured rat oligodendrocytes by complement. Immunology, 67, 441–446

    PubMed  CAS  Google Scholar 

  35. Shirazi, Y., Macklin, W. B. and Shin, M. L. (1989). Terminal complement complexes (TCC) inhibit myelin protein mRNA expression in oligodendrocytes. FASEB J., 3, A2017 (abstract)

    Google Scholar 

  36. Lublin, F. D. (1985). Relapsing experimental allergic encephalomyelitis a autoimmune model of multiple sclerosis. Springer Semin. Immunopathol., 8, 197–208

    Article  PubMed  CAS  Google Scholar 

  37. Linington, C, Bradl, M., Lassmann, H., Brunner, C. and Vass, K. (1988). Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein (MOG). Am. J. Pathol., 130, 443–454

    PubMed  CAS  Google Scholar 

  38. Ben-Nun, A., Wekerle, H. and Cohen, I. R. (1981). The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol., 11, 195–199

    Article  PubMed  CAS  Google Scholar 

  39. Pabst, H., Day, N. K., Gewurz, H. and Good, R. A. (1971). Prevention of experimental allergic encephalomyelitis with cobra venom factor. Proc. Soc. Exp. Biol. Med., 136, 555–560

    PubMed  CAS  Google Scholar 

  40. Levine, S., Cochran, C. G. and Carpenter, C. B. (1977). Allergic encephalomyelitis: effect of complement depletion with cobra venom. Proc. Soc. Exp. Biol. Med., 138, 285–289

    Google Scholar 

  41. Morariau, M. A. and Dalmasso, A. P. (1978). Experimental allergic encephalomyelitis in cobra venom factor-treated and C4-deficient guinea pigs. Ann. Neurol., 4, 427–430

    Article  Google Scholar 

  42. Linington, C, Morgan, B. P., Scolding, N. J., Piddlesden, S., Wilkins, P. and Compston, D. A. S. (1989). The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain, 112, 895–911.

    Article  PubMed  Google Scholar 

  43. Piddlesden, S., Lassmann, H., Laffafian, I., Morgan, B. P. and Linington, C. (1990). Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane complex formation. Clin. Exp. Immunol., 83, 245–250

    Article  Google Scholar 

  44. Linington, C, Lassmann, H., Morgan, B. P. and Compston, D. A. S. (1989). Immuno-histochemical localisation of complement component C9 in experimental allergic encephalomyelitis. Acta Neuropathol., 79, 78–85

    Article  PubMed  CAS  Google Scholar 

  45. Kuweit, E., Pette, E., Firnhaber, W. and Mai, K. (1965). Demonstration of complement in spinal fluid in multiple sclerosis. Ann. NY Acad. Sci., 122, 429–435

    Google Scholar 

  46. Link, H. (1972). Complement factors in multiple sclerosis. Acta Neurol. Scand., 48, 521–528

    Article  PubMed  CAS  Google Scholar 

  47. Trouillas, P., Moindrot, J., Betuel, H., Quinay, Cl., Aimard, G. and Devic, M. (1976). Scleroses en plaques avec hypocomplementemie et scleroses en plaques normocomplementaires correlation cliniques et genetiques. Rev. Neurol. (Paris), 132, 681–704

    Google Scholar 

  48. Caspary, E. A. (1977). Humoral factors involved in immune processes in multiple sclerosis and allergic encephalomyelitis. Br. Med. Bull., 33, 50–53

    PubMed  CAS  Google Scholar 

  49. Yam, P., Petz., L. D., Tourellote, W. W. and Ma, B. I. (1980). Measurement of complement components in cerebral spinal fluid by radioimmunoassay in patients with multiple sclerosis. Clin. Immunol. Immunopathol., 17, 492–505

    Article  PubMed  CAS  Google Scholar 

  50. Morgan, B. P., Campbell, A. K. and Compston, D. A. S. (1984). Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis. Lancet, 2, 251–254

    Article  PubMed  CAS  Google Scholar 

  51. Compston, D. A. S., Morgan, B. P., Oleesky, D., Fifield, R. and Campbell, A. K. (1986). Cerebrospinal fluid C9 in demyelinating disease. Neurology, 36, 1503–1506

    Article  PubMed  CAS  Google Scholar 

  52. Halawa, I., Lolli, F. and Link, H. (1989). Terminal component of complement C9 in CSF and plasma of patients with MS and aseptic meningitis. Acta Neurol. Scand., 80, 130–135

    Article  PubMed  CAS  Google Scholar 

  53. Rodriguez, M., Wynn, D. R., Kimlinger, T. K. and Katzmann, J. A. (1990). Terminal component of complement (C9) in the cerebrospinal fluid of patients with multiple sclerosis and neurological controls. Neurology, 40, 855–857

    Article  PubMed  CAS  Google Scholar 

  54. Sanders, M. E., Koski, C. L., Robbins, D., Shin, M. L., Frank, M. M. and Joiner, K. A. (1986). Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J. Immunol., 135, 4456–4459

    Google Scholar 

  55. Mollnes T. E. Vandvick B. Lea T. and Vartdal F. 1987. Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex. J. Neurol. Sci. 78 17–2

    Google Scholar 

  56. Compston, D. A. S., Morgan, B. P., Campbell, A. K., Wilkins, P., Cole, G., Thomas, N. D. and Jasani, B. (1989). Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol. Appl. Neurobiol., 15, 307–316

    Article  PubMed  CAS  Google Scholar 

  57. Smith K. J. Hall S. M. and Schauf C. L. 1985. Vesicular demyelination induced by raised intracellular calcium. J. Neurol. Sci. 71 19–3

    Google Scholar 

  58. Smith K. J. and Hall S. M. 1988. Peripheral demyelination and remeylination initiated by the calcium-selective iophore iomycin in vivo observations. J. Neurol. Sci. 83 37–5

    Google Scholar 

  59. Waxman, S. G., Davis, P. K., Black, J. A. and Ransom, B. R. (1990). Anoxic injury of mammalian central white matter: decreased susceptibility in myelin-deficient optic nerve. Ann. Neurol., 28, 335–340

    Article  PubMed  CAS  Google Scholar 

  60. Asbury A. K. 1990. Guillain-Barre syndrome Historical aspects. Ann. Neurol. 27 suppl. S2–S

    Google Scholar 

  61. Alter M. 1990. The epidemiology of Guillain-Barre syndrome. Ann. Neurol. 27 suppl. S7–S1

    Google Scholar 

  62. Prineas J. W. 1981. Pathology of the Guillain-Barre syndrome. Ann. Neurol. 9 suppl. S6–S1

    Google Scholar 

  63. Astrom K. E. and Waksman B. H. 1962. The passive transfer of experimental encephalomyelitis and neuritis with living lymphoid cells. J. Pathol. Bacteriol., 83, 39–10

    Article  Google Scholar 

  64. Carlo, D. J., Karkhanis, Y. D. and Bailey, P. J. (1975). Experimental neuritis: evidence for the involvement of the P0 and P2 proteins. Brain Res., 88, 580–584

    Article  PubMed  CAS  Google Scholar 

  65. Cook, S. D., Dowling, P. C. and Whitaker, J. N. (1970). The Guillain-Barre syndrome: relationship of circulating immunocytes to disease activity. Arch. Neurol., 22, 470–474

    Article  PubMed  CAS  Google Scholar 

  66. Iquabal, A., Oger, J. J-F. and Arnason, B. G. W. (1981). Cell-mediated immunity in idiopathic polyneuritis. Ann. Neurol., 9 (suppl.), S65–S69

    Article  Google Scholar 

  67. Cook S. Dowling P. C Murray M. R. and Whitaker J. N. 1971. Circulating demyelinating factors in acute idiopathic polyneuropathy myelitoxic antibody in the Guillain-Barre syndrome. Arch. Neurol. 24 136–14

    Google Scholar 

  68. Saida, T., Saida, K. and Lisak, R. P. (1982). In vivo demyelinating activity of sera from patients with Guillain-Barre syndrome. Ann. Neurol., 11, 69–75

    Article  PubMed  CAS  Google Scholar 

  69. Nyland, H. and Aarli, J. A. (1978). Guillain-Barre syndrome: demonstration of antibodies to peripheral nerve tissue. Acta Neurol. Scand., 58, 35–43

    Article  PubMed  CAS  Google Scholar 

  70. Koski, C. L., Gratz., E., Sutherland, J. and Mayer, R. F. (1986). Clinical correlation with anti-peripheral nerve myelin antibodies in Guillain-Barre syndrome. Ann. Neurol., 19, 573–577

    Article  PubMed  CAS  Google Scholar 

  71. Koski, C. L., Chou, D. K. H. and Jungalwala, F. B. (1989). Antiperipheral nerve myelin antibodies in Guillain-Barre syndrome bind a neutral glycolipid of peripheral myelin and cross-react with Forssman antigen. J. Clin. Invest., 84, 280–287

    Article  PubMed  CAS  Google Scholar 

  72. Koski, C. L. (1990). Characterisation of complement-fixing antibodies to peripheral nerve myelin in Guillain-Barre syndrome. Ann. Neurol., 27 (suppl.), S44–S47

    Article  PubMed  Google Scholar 

  73. McKhann, G. M., Griffin, J. W., Cornblath, D. R., Mellits, E. D., Fisher, R. S. and Quaskey, S. A. (1988). Plasmapheresis and Guillain-Barre syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann. Neurol., 23, 347–353

    Article  PubMed  CAS  Google Scholar 

  74. Hartung, H-P., Schwenke, C, Bitter-Suermann, D. and Toyka, K. V. (1987). Guillain-Barre syndrome: activated complement components C3a and C5a in CSF. Neurology, 37, 1006–1009

    Article  PubMed  CAS  Google Scholar 

  75. Koski C. L. Sanders M. E. Swoveland P. T. Lawley T. J. Shin M. L. Frank M. M. and Joiner K. A. 1987. Activation of terminal components of complement in patients with Guillain-Barre syndrome and other demyelinating neuropathies. J. Clin. Invest. 80 1492–149

    Google Scholar 

  76. Latov., N., Sherman W. H., Nemni, R., Galasi, G., Shyong, J. S., Penn, A. S., Chess, L., Orlate, M. R., Rowland, L. P. and Osserman, E. F. (1980). Plasma cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral nerve myelin. N. Engl. J. Med., 303, 618–621

    Article  PubMed  CAS  Google Scholar 

  77. Latov, N., Gross, R. B., Kastelman, J., Flanagan, T., Lamme, S., Alkaitis, D. A., Olarte, M. R., Sherman, W. H., Chess, L. and Penn, A. S. (1981). Complement-fixing anti-peripheral nerve myelin antibodies in patients with inflammatory polyneuritis and polyneuropathy and paraproteinaemia. Neurology, 31, 1530–1534

    Article  PubMed  CAS  Google Scholar 

  78. Ilyas, A. A., Quarles, R. H., Macintosh, I. D., Dobersen, M. J., Trapp, B. D., Dalakas, M. C. and Brady, R. O. (1984). IgM in a human neuropathy related to paraproteinaemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside. Proc. Natl. Acad. Sci. USA, 81, 1225–1229

    Article  PubMed  CAS  Google Scholar 

  79. Hays, A. P., Latov, N., Takasu, M. and Sherman, W. H. (1987). Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein. Neurology, 37, 242–256

    Article  PubMed  CAS  Google Scholar 

  80. Haas, D. C. and Tatum, A. H. (1988). Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinaemia. Ann. Neurol., 23, 394–396

    Article  PubMed  CAS  Google Scholar 

  81. Hays, A. P., Lee, S. and Latov, N. (1988). Immune reactive C3d on the surface of myelin sheaths in neuropathy. J. Neuroimmunol., 18, 231–244

    Article  PubMed  CAS  Google Scholar 

  82. Monaco, S., Bonetti, B., Ferrari, S., Moretto, G., Nardelli, E., Tedesco., F., Mollnes, T. E., Nobile-Orazio, E., Manfredini, E., Bonazzi, L. and Rizzuto, N. (1990). Complement-mediated demyelination in patients with IgM monoclonal gammopathy and peripheral neuropathy. N. Engl. J. Med., 322, 649–652

    Article  PubMed  CAS  Google Scholar 

  83. Monaco S. Ferrari S. Nardelli E. Bonetti B. Rizzuto N. and Tedesco F. 1990. Experimental models for complementmediated demyelination. Complement Inflamm. 7 138 abstract

    Google Scholar 

  84. Borsos, T. and Rapp, H. J. (1965). Complement fixation on cell surfaces by 19S and 7S antibodies. Science, 150, 505–506

    Article  PubMed  CAS  Google Scholar 

  85. Borsos, T., Chapuis, M. and Langone, J. J. (1981). Distinction between fixation of Cl and the activation of complement by natural IgM anti-hapten antibody: Effect of cell surface hapten density. Mol. Immunol., 18, 863–868

    Article  PubMed  CAS  Google Scholar 

  86. Borsos, T. and Circolo, A. (1983). Binding and activation of Cl by cell bound IgG: Activation depends on cell surface hapten density. Mol. Immunol., 20, 433–438

    Article  PubMed  CAS  Google Scholar 

  87. Newsome-Davis, J. and Vincent, A. (1982). Myasthenia gravis. In Lachmann, P. J. and Peters, D. K. (eds.) Clinical Aspects of Immunology, pp. 1011–1068. (Oxford: Blackwell)

    Google Scholar 

  88. Campbell, H. and Bramwell, E. (1990). Myasthenia gravis. Brain, 23, 277–336

    Article  Google Scholar 

  89. Wilson, A. and Stoner, H. B. (1944). Myasthenia gravis. A consideration of its causation in fourteen cases. Q. J. Med., 13, 1–18

    CAS  Google Scholar 

  90. Teng P. and Osserman K. E. 1956. Studies in myasthenia gravis neonatal and juvenile types. J. Mt. Sinai Hosp. 23 711–72

    Google Scholar 

  91. Strauss, A. J. L., Deitch, A. and Hsu, K. C. (1961). Further observations on the localization of a muscle-binding complement-fixing serum globulin fraction in myasthenia gravis. Fed. Proc, 20, 38 (abstract)

    Google Scholar 

  92. Parkes, J. D. and McKinna, J. A. (1966). Neuromuscular blocking activity in the blood of patients with myasthenia gravis. Lancet, 1, 338–391

    Google Scholar 

  93. Van der Geld H. Feltkamp T. E. W. and Oosterhuis H. J. G. H. 1964. Reactivity of myasthenia gravis serum y-globulin with skeletal muscle and thymus demonstrated by immufluorescence. Proc. Soc. Exp. Biol. Med. 115 782–78

    Google Scholar 

  94. Fambrough, D. M., Drachman, D. B. and Satyamurti, S. (1973) Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science, 182, 293–295

    Article  PubMed  CAS  Google Scholar 

  95. Patrick J. and Lindstrom J. 1973. Autoimmune response to acetylcholine receptor. Science 189 871–87

    Google Scholar 

  96. Tarab-Hazdai, R., Aharanov, A., Silbman, I., Fuchs, S. and Abramsky, O. (1975). Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. Nature, 256, 128–130

    Article  Google Scholar 

  97. Nastuk, W. L., Plescia, O. and Osserman, K. E. (1960). Changes in serum complement levels in patients with myasthenia gravis. Proc. Soc. Exp. Med., 105, 177–184

    CAS  Google Scholar 

  98. Plescia, O. J., Segovia, J. M. and Strampp, A. (1966). An assessment of changes in the complement level of myasthenic sera. Ann. N. Y. Acad. Sci., 135, 580–587

    Article  PubMed  CAS  Google Scholar 

  99. Engel, A. G., Lambert, E. H. and Howard, F. M. (1977). Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis. Ultra-structural and light microscopical localization and electrophysiological correlations. Mayo Clin. Proc, 52, 267–280

    PubMed  CAS  Google Scholar 

  100. Sahashi K. Engel A. G. Lambert E. H. and Howard F. M. 1980. Ultrastructural localization of the terminal and lytic 9th complement component C9 at the motor end-plate in myasthenia gravis. J. Neurol. Exp. Neuropathol. 39 160–17

    Google Scholar 

  101. Engel, A. G. and Arahata, K. (1987). The membrane attack complex of complement at the motor end-plate in myasthenia gravis. Ann. NY Acad. Sci., 505, 326–332

    Article  PubMed  CAS  Google Scholar 

  102. Engel, A. G., Sakakibara, H., Sahashi, K., Lindstrom, J. M., Lambert, E. H. and Lennon, V. A. (1979). Passively transferred experimental autoimmune myasthenia gravis: sequential and quantitative studies of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor. Neurology, 29, 179–188

    Article  PubMed  CAS  Google Scholar 

  103. Lenn V. A. Seybold M. E. Lindstrom J. M. Cochrane C. and Ulevitch R. 1978. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147 973–98

    Google Scholar 

  104. Biesecker G. and Gomez C. M. 1989. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J. Immul. 142 2654–265

    Google Scholar 

  105. Engel, A. G. and Fumagalli, G. (1982). Mechanisms of acetylcholine receptor loss from the neuromuscular junction. In Receptors, Antibodies and Disease. CIBA Foundation Symposium 90, pp. 197–224. (London: Pitma

    Google Scholar 

  106. Hulette, C. M. and Walford, R. L. (1987). Immunological aspects of Alzheimer disease: a review. Alzheimer Dis. Assoc. Discord., 1, 72–82

    Article  CAS  Google Scholar 

  107. Giometto, B., Argentiero, V., Sanson, F., Ongaro, G. and Tavolato, B. (1988). Acute phase proteins in Alzheimer’s disease. Eur. Neurol., 28, 30–33

    Article  PubMed  CAS  Google Scholar 

  108. Eikelenboom, P. and Stam, F. C. (1982). Immunoglobulins and complement factors in senile plaques: an immunohistoperoxidase study. Acta Neuropathol., 57, 239–242

    Article  PubMed  CAS  Google Scholar 

  109. Ishii, T., Haga, S. and Akiyama, H. (1988). Presence of immunoglobulins and complement in the amyloid plaques in the brain of patients with Alzheimer’s disease. In Pouplard-Barthelaix, Emile and Christen (eds.) Immunology and Alzheimer’s Disease, pp. 17–29. (Berlin: Springer)

    Chapter  Google Scholar 

  110. Eikelenboom, P., Hack, C. E., Rozemuller, J. M. and Stam, F. C. (1989). Complement activation in amyloid plaques in Alzheimer’s dementia. Virchow’s Arch. (Cell Pathol.), 56, 259–262

    Article  CAS  Google Scholar 

  111. McGeer, P. L., Akinyama, H., Iltagaki, S. and McGeer, E. G. (1989). Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett., 107, 341–346

    Article  PubMed  CAS  Google Scholar 

  112. Yamada, T., Akiyama, H. and McGeer, P. L. (1990). Complement-activated oligodendrocytes: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d. Neurosci. Lett., 112, 161–166

    Article  PubMed  CAS  Google Scholar 

  113. Ostergard J. R. Kristensen B. O. Svehag S. E. Teisner B. and Miletic T. 1987. Immune complexes and complement activation following rupture of intracranial saccular aneurysms. J. Neurosurg. 66 891–90

    Google Scholar 

  114. Kasuya, H. and Shimizu, T. (1989). Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid haemorrhage. J. Neurosurg., 71, 741–746

    Article  PubMed  CAS  Google Scholar 

  115. Hollerhage, H. G., Wilgand, H. and Stolke, D. (1986). The effect of the cleavage peptide C3adesArg of the third complement component on the accumulation of leukocytes in cerebrospinal fluid (CSF) and on the permeability of the blood-CSF barrier. In Wenker, H., Klinger, M. and Brock, M. (eds.) Advances in Neurosurgery, 14, pp. 252–256. (Berlin: Springer)

    Google Scholar 

  116. Hollerhage, H. G. (1988). Possible role of complement peptides in SAH. J. Neurosurg., 69, 802–803

    PubMed  CAS  Google Scholar 

  117. Small, P., Mass, M. F., Kohler, P. F. and Harbeck, R. J. (1977). Central nervous system involvement in SLE. Diagnostic profile and clinical features. Arthritis Rheum., 20, 869–978

    Article  PubMed  CAS  Google Scholar 

  118. Johnson, R. T. and Richardson, E. P. (1968). The neurological manifestations of systemic lupus erythematosus. Medicine, 47, 337–369

    Article  PubMed  CAS  Google Scholar 

  119. Ellis, S. G. and Verity, M. A. (1979). Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1975-1977. Semin. Arthritis Rheum., 8, 212–221

    Article  PubMed  CAS  Google Scholar 

  120. Petz, L. D., Sharp, G. C, Cooper, N. R. and Irvin, W. S. (1971). Serum and cerebral spinal fluid complement and serum autoantibodies in systemic lupus erythematosus. Medicine, 50, 259–575

    Article  PubMed  CAS  Google Scholar 

  121. Hadler N. M. Gerwin R. D. Frank M. M. Whitaker J. N. Baker M. and Decker J. L. 1973. The fourth component of complement in the cerebrospinal fluid in systemic lupus erythematosus. Arthritis Rheum. 16 507–52

    Google Scholar 

  122. Sanders, M. E., Alexander, E. L., Koski, C. L., Frank, M. M. and Joiner, K. A. (1987). Detection of activated terminal complement (C5b-9) in cerebrospinal fluid from patients with central nervous system involvement of primary Sjogren’s syndrome or systemic lupus erythematosus. J. Immunol., 138, 2095–2099

    PubMed  CAS  Google Scholar 

  123. Bluestein, H. G., Williams, G. W. and Steinberg, A. D. (1981). Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am. J. Med., 70, 240–246

    Article  PubMed  CAS  Google Scholar 

  124. Seibold, J. R., Buckingham, R. B., Medsger, T. A. Jr. and Kelly, R. H. (1982). Cerebrospinal fluid immune complexes in systemic lupus erythematosus involving the central nervous system. Semin. Arthritis Rheum., 12, 68–76

    Article  PubMed  CAS  Google Scholar 

  125. Alexander, G. E., Provost, T. T., Stevens, M. B. and Alexander, E. L. (1982). Sjogren’s syndrome: central nervous system manifestations. Neurology, 31, 1391–1396

    Article  Google Scholar 

  126. Alexander, E. L., Lijewski, J. E., Jordan, M. S. and Alexander, G. E. (1986). Evidence of an immunopathogenic basis for central nervous system disease in primary Sjogren’s syndrome. Arthritis Rheum., 29, 1223–1231

    Article  PubMed  CAS  Google Scholar 

  127. Harriman, G. R., Esser, A. F., Podack, E. R., Wunderlich, A. C, Braude, A. I., Lint, T. F. and Curd, J. G. (1980). The role of C9 in complement-mediated killing of Neisseria. J. Immunol., 125, 2252–2257

    Google Scholar 

  128. Ross, S. C. and Densen, P. (1984). Complement deficiency states and infection: Epidemiology, pathogenesis and consequences of Neisserial and other infections in an immune deficiency. Medicine, 63, 243–273

    Article  PubMed  CAS  Google Scholar 

  129. Fries, L. F., O’shea, J. J. and Frank, M. M. (1986). Inherited deficiencies of complement and complement-related proteins. Clin. Immunol. Immunopathol., 40, 37–39

    Article  PubMed  CAS  Google Scholar 

  130. Fijen, C. A. P., Kuijper, E. J., Hannema, A. J., Sjoholm, A. G. and van Putten, J. P. M. (1989). Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups. Lancet, 2, 585–588

    Article  PubMed  CAS  Google Scholar 

  131. Inai S. H. Kitamura S. Hiramatsu S. and Nagaki K. 1979. Deficiency of the ninth component of complement in man. J. Clin. Invest. 71 183–19

    Google Scholar 

  132. Inaba, S., Okochi, K., Fukada, K., Kinoshita, S., Maeda, Y. and Yoshinari, M. (1987). The occurrence of precipitating antibodies in transfused Japanese patients with hereditary ninth component of complement deficiency and frequency of C9 deficiency. Transfusion, 27, 475–477

    Article  PubMed  CAS  Google Scholar 

  133. Fukumori, Y., Yoshimuro, K. and Ohnoki, S. (1989). A high incidence of C9 deficiency among healthy blood donors in Osaka, Japan. Int. Immunol., 1, 85–89

    Article  PubMed  CAS  Google Scholar 

  134. Nagata, M., Hara, T., Aoki, T., Mizuno, Y., Akeda, H., Inaba, S., Tsumoto, K. and Ueda, K. (1989). Inherited deficiency of ninth component of complement: An increased risk of meningococcal meningitis. J. Paediatr., 114, 260–264

    Article  CAS  Google Scholar 

  135. Sjoholm, A. G., Braconier, J-H. and Soderstrom, C. (1982). Properdin deficiency in a family with fulminant meningococcal infections. Clin. Exp. Immunol., 50, 291–297

    PubMed  CAS  Google Scholar 

  136. Sjoholm, A. G., Kuijper, E. J., Tijssen, C. C, Jansz, A., Bol, P., Spanjaard, L. and Zanen, H. C. (1988). Dysfunctional properdin in a Dutch family with meningococcal disease. N. Engl. J. Med., 319, 33–37

    Article  PubMed  CAS  Google Scholar 

  137. Sjoholm, A. G., Soderstrom, C. and Nilsson, L.-A. (1988). A second variant of properdin deficiency: The detection of properdin at low concentrations in affected males. Complement, 5, 130–140

    PubMed  CAS  Google Scholar 

  138. Hiemstra, P. S., Langeler, E., Compier, B., Keepers, Y., Leijh, P. C. J., van den Barselaar, M. T., Overbosch, D. and Daha, M. R. (1989). Complete and partial deficiencies of complement factor D in a Dutch family. J. Clin. Invest., 84, 1957–1961

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. B. P. Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Immunology, University of Leicester, Leicester, UK

    K. Whaley

  2. Institut für Medizinische Mikrobiologie, University of Mainz, Mainz, Germany

    M. Loos

  3. University of Iowa, Iowa City, Iowa, USA

    J. M. Weiler

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Morgan, B.P. (1993). Complement in diseases of the nervous system. In: Whaley, K., Loos, M., Weiler, J.M. (eds) Complement in Health and Disease. Immunology and Medicine, vol 20. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-2214-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-2214-6_13

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-4981-8

  • Online ISBN: 978-94-011-2214-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation